UniXell
Shanghai
About UniXell
UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $31.4M
- Funding stage: Seed
- Last round: Seed (Mar 2022)
- Website: unixell.com
- Phone: +86 21-60197620
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/unixell-114626 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.